Skip to main content
. 2022 Nov 11;14(22):9000–9019. doi: 10.18632/aging.204377

Figure 9.

Figure 9

The flow chart of NAP1L5 targeting combined with MYH9 Inhibit HCC progression. NAP1L5 targets and binds MYH9 to regulate cycle, apoptosis, EMT-related protein expression and PI3K/AKT/mTOR signal pathway activity, thus inhibiting the progression of hepatocellular carcinoma.